Clinical trials: Urinary System Tumor
Non-Muscle-Invasive Bladder Cancer
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or…
- Trial name
- NCT06327932
- Testing
- TURBT, HIVEC, Intravesical Chemotherapy
- Volunteers
- 320 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.
Kidney Neoplasms
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
Background: Some patients with advanced kidney cancer have immune cells that can recognize and kill their cancer, but the cells are not active enough or numerous enough to accomplish this on their own.
- Trial name
- NCT00091611
- Testing
- IL-2 (interleukin-2), OKT3, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
- Trial name
- NCT00186277
- Testing
- Oxaliplatin, Taxotere
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Neoplasms, Carcinoma, Renal Cell
Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery for Renal Tumor.
Investigators aimed to estimate the effect of showing and handling a three-dimensional modelization of a patient's kidney presenting with tumor the day before his nephron-sparing surgery.
- Trial name
- R3DP-A (NCT03943771)
- Testing
- Anxiety, renal anatomy and surgery questionnaires
- Where
- France
- Sponsor
- University Hospital, Bordeaux
Bladder Cancer
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual…
- Trial name
- NCT06525571
- Testing
- Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Kidney Cancer
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.
- Trial name
- NCT00006864
- Testing
- aldesleukin
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Clear-cell Metastatic Renal Cell Carcinoma
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy.
- Trial name
- A-PREDICT (NCT01693822)
- Testing
- Axitinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Carcinoma, Renal Cell
Long-term Extension From RCC Phase II (11515)
Extension to study 11515 (NCT00661375) which was a multicenter study of sorafenib in patients with renal cell carcinoma (RCC).
- Trial name
- NCT00586495
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 41 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Bayer
Arrhythmia, Cardiac, Kidney Cancer
Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method
This study evaluates the incidence of cardiac arrhythmias during the perioperative period in patients undergoing open kidney cancer surgery in the lateral position.
- Conditions
- Arrhythmia, Cardiac, Kidney Cancer, Surgery, Anesthesia, Local
- Trial name
- NCT02988219
- Testing
- Bupivacaine-fentanyl, Holter ECG monitor, Open kidney cancer surgery
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Medical University of Warsaw
Renal Malignant Tumor, Renal Tumor
Normotonic Partial Nephrectomy as Novel Approach in Treating Small Renal Masses
This study evaluates novel surgical approach in treating small renal masses. Half of participants will undergo hypotonic zero-ischaemia partial nephrectomy (standard of care), while the other half will undergo normotonic…
- Trial name
- NORPN (NCT04096534)
- Testing
- Normotonic partial nephrectomy, Hypotonic partial nephrectomy
- Where
- Russia
- Volunteers
- 108 people
- Sponsor
- Saint Petersburg State University, Russia
Collecting Duct Carcinoma
Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)
Collect a large number of samples with certain / suspected diagnosis of collecting duct carcinoma in order to confirm the diagnosis (centralized review) and standardize according to WHO 2016 criteria Build an extensive tissue…
- Trial name
- CICERONE (NCT05372302)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Urinary Bladder Cancer
Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis…
- Trial name
- NCT02720367
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Taris Biomedical LLC
Bladder Cancer, Prostate Cancer
Robot-assisted Urological Surgeries Using the MicroHand S Robot
A single-blinded, prospective randomized parallel controlled clinical trial is designed and will be conducted from July 2022 to November 2023 (anticipated).
- Conditions
- Bladder Cancer, Prostate Cancer, Renal Cancer
- Trial name
- NCT05462392
- Testing
- robot-assisted surgery
- Where
- China
- Volunteers
- 136 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Non-muscle Invasive Bladder Cancer
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
This study is an open-label dose escalation study (Phase 1a) to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of…
- Trial name
- ADVANCED-1 (NCT05085977)
- Testing
- TARA-002
- Where
- 14 sites in United States, Moldova and 2 more
- Volunteers
- 12 people
- Sponsor
- Protara Therapeutics
Metastatic Renal Cell Carcinoma
A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
A SU011248 expanded access protocol for systemic therapy of patients with metastatic Renal Cell Carcinoma who are ineligible for participation in other SU011248 protocols but may derive benefit from treatment with SU011248
- Trial name
- NCT00531544
- Testing
- SU011248
- Where
- Saudi Arabia
- Volunteers
- 350 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Metastatic Melanoma, Metastatic Renal Cell Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Background: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor.
- Conditions
- Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
- Trial name
- NCT00670748
- Testing
- Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Endometrial Cancer
Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors
This randomized pilot clinical trial studies pelvic floor muscle training in treating urinary incontinence in gynecologic cancer survivors.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor
- Trial name
- NCT01806350
- Testing
- questionnaire administration, standard follow-up care, educational intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- New Mexico Cancer Research Alliance
Advanced Cancer, Clear Cell Renal Cell Carcinoma
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT05663710
- Testing
- 177Lu girentuximab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.